{"id":37565,"date":"2025-11-03T14:22:19","date_gmt":"2025-11-03T07:22:19","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=37565"},"modified":"2025-11-03T14:22:19","modified_gmt":"2025-11-03T07:22:19","slug":"gc-biopharmas-recombinant-anthrax-vaccine-barythrax-demonstrates-safety-and-immunogenicity-in-phase-2-data-published-in-vaccine","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=37565","title":{"rendered":"GC Biopharma’s Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in ‘Vaccine’"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

YONGIN, South Korea<\/span><\/span>, Nov. 3, 2025<\/span><\/span> \/PRNewswire\/ — GC Biopharma, a leading global pharmaceutical company based in South Korea<\/span>, announced today that the Phase 2 clinical trial results for its anthrax vaccine ‘BARYTHRAX inj. (GC1109)’ have been published in the international journal\u00a0Vaccine<\/i>. BARYTHRAX is the world’s first recombinant anthrax vaccine, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA).<\/p>\n

\n<\/div>\n

This randomized, double-blind, placebo-controlled Phase 2 clinical trial, approved by the Ministry of Food and Drug Safety (MFDS) was conducted to evaluate the safety and immunogenicity of the vaccine. A total of 240 healthy adult subjects were recruited across five hospitals in Korea: Seoul National University<\/span> Hospital, The Catholic University<\/span> of Korea St. Vincent’s Hospital, Korea University Ansan Hospital, Soon Chun Hyang University Hospital Seoul, and Hallym University Sacred Heart Hospital. After administration of either BARYTHRAX or a placebo, the clinical research team assessed the participants for antibody production and any adverse reactions.<\/p>\n

The Phase 2 clinical trial demonstrated that the vaccine elicited antibodies that neutralized the anthrax toxin at a level exceeding the pre-defined protective threshold. This finding indicates robust immunogenicity and suggests that BARYTHRAX can provide clinically meaningful protection against anthrax infection.<\/p>\n

In addition, safety assessments showed that the adverse events in the BARYTHRAX group, such injection site pain, myalgia, fatigue, and malaise, were mostly mild and temporary. No cases of acute adverse reactions or deaths were reported, confirming a favorable safety profile for the vaccine.<\/p>\n

GC Biopharma emphasized that, BARYTHRAX has the significant advantage of being more safe than traditional methods that use live attenuated bacteria and allowing for rapid mass production when needed.<\/p>\n

Dr. Nam Joong Kim<\/span>, the principal investigator of the clinical trial and a professor at Seoul National University<\/span> Hospital, stated, “This clinical research exemplifies successful academia-industry collaboration and represents a significant milestone in the development of safe and effective vaccines.”<\/p>\n

He added, “We anticipate that the successful development of Korea’s first recombinant anthrax vaccine will serve as a stepping stone for advancing research on infectious diseases and boosting vaccine localization.”<\/p>\n

“We are thrilled to have our study result published in a globally renowned academic journal Vaccine<\/i>, once again recognizing its clinical significance and value,” said Dr. Chang Kyung Kang<\/span> of Seoul National University<\/span> Hospital, the lead author of the publication.<\/p>\n

“The clinical trial has successfully demonstrated the\u00a0efficacy and safety\u00a0of BARYTHRAX,” commented Jae-Uk Jeong<\/span>, Head of R&D at GC Biopharma. “This\u00a0domestically developed\u00a0anthrax vaccine is poised to make a significant contribution to\u00a0strengthening our national pandemic preparedness.”<\/p>\n

[Reference]<\/b><\/p>\n

Barythrax Inj.<\/b><\/p>\n

This vaccine is the world’s first recombinant protein-based anthrax vaccine and Korea’s 39th<\/sup> New Drug and 3rd<\/sup> New Drug Vaccine.<\/p>\n

The vaccine is produced using recombinant technology to express and purify solely the Protective Antigen (PA) protein from\u00a0Bacillus anthracis<\/i>, the key component of the anthrax toxin.<\/p>\n

Anthrax<\/b><\/p>\n

Anthrax is a zoonotic disease that can infect both humans and animals. It is classified as a potential bioterrorism agent as the aerosolized anthrax spores can cause fatal respiratory infections.<\/p>\n

About GC Biopharma<\/b><\/p>\n

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea<\/span>. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo\u2122(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit https:\/\/www.gcbiopharma.com\/eng\/<\/a><\/p>\n

This press release may contain<\/i>\u00a0biopharmaceuticals\u00a0in forward-looking statements, which express the current beliefs and expectations of GC Biopharma’s management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.<\/i><\/p>\n

GC Biopharma Contacts (Media)<\/b><\/p>\n

Sohee Kim<\/span><\/p>\n

shkim20@gccorp.com<\/a><\/p>\n

Yelin Jun<\/span><\/p>\n

yelin@gccorp.com<\/a><\/p>\n

Yoonjae Na<\/span><\/p>\n

yjy6520@gccorp.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

YONGIN, South Korea<\/span><\/span>, Nov. 3, 2025<\/span><\/span> \/PRNewswire\/ — GC Biopharma, a leading global pharmaceutical company based in South Korea<\/span>, announced today that the Phase 2 clinical trial results for its anthrax vaccine ‘BARYTHRAX inj. (GC1109)’ have been published in the international journal\u00a0Vaccine<\/i>. BARYTHRAX is the world’s first recombinant anthrax vaccine, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA).<\/p>\n

\n<\/div>\n

This randomized, double-blind, placebo-controlled Phase 2 clinical trial, approved by the Ministry of Food and Drug Safety (MFDS) was conducted to evaluate the safety and immunogenicity of the vaccine. A total of 240 healthy adult subjects were recruited across five hospitals in Korea: Seoul National University<\/span> Hospital, The Catholic University<\/span> of Korea St. Vincent’s Hospital, Korea University Ansan Hospital, Soon Chun Hyang University Hospital Seoul, and Hallym University Sacred Heart Hospital. After administration of either BARYTHRAX or a placebo, the clinical research team assessed the participants for antibody production and any adverse reactions.<\/p>\n

The Phase 2 clinical trial demonstrated that the vaccine elicited antibodies that neutralized the anthrax toxin at a level exceeding the pre-defined protective threshold. This finding indicates robust immunogenicity and suggests that BARYTHRAX can provide clinically meaningful protection against anthrax infection.<\/p>\n

In addition, safety assessments showed that the adverse events in the BARYTHRAX group, such injection site pain, myalgia, fatigue, and malaise, were mostly mild and temporary. No cases of acute adverse reactions or deaths were reported, confirming a favorable safety profile for the vaccine.<\/p>\n

GC Biopharma emphasized that, BARYTHRAX has the significant advantage of being more safe than traditional methods that use live attenuated bacteria and allowing for rapid mass production when needed.<\/p>\n

Dr. Nam Joong Kim<\/span>, the principal investigator of the clinical trial and a professor at Seoul National University<\/span> Hospital, stated, “This clinical research exemplifies successful academia-industry collaboration and represents a significant milestone in the development of safe and effective vaccines.”<\/p>\n

He added, “We anticipate that the successful development of Korea’s first recombinant anthrax vaccine will serve as a stepping stone for advancing research on infectious diseases and boosting vaccine localization.”<\/p>\n

“We are thrilled to have our study result published in a globally renowned academic journal Vaccine<\/i>, once again recognizing its clinical significance and value,” said Dr. Chang Kyung Kang<\/span> of Seoul National University<\/span> Hospital, the lead author of the publication.<\/p>\n

“The clinical trial has successfully demonstrated the\u00a0efficacy and safety\u00a0of BARYTHRAX,” commented Jae-Uk Jeong<\/span>, Head of R&D at GC Biopharma. “This\u00a0domestically developed\u00a0anthrax vaccine is poised to make a significant contribution to\u00a0strengthening our national pandemic preparedness.”<\/p>\n

[Reference]<\/b><\/p>\n

Barythrax Inj.<\/b><\/p>\n

This vaccine is the world’s first recombinant protein-based anthrax vaccine and Korea’s 39th<\/sup> New Drug and 3rd<\/sup> New Drug Vaccine.<\/p>\n

The vaccine is produced using recombinant technology to express and purify solely the Protective Antigen (PA) protein from\u00a0Bacillus anthracis<\/i>, the key component of the anthrax toxin.<\/p>\n

Anthrax<\/b><\/p>\n

Anthrax is a zoonotic disease that can infect both humans and animals. It is classified as a potential bioterrorism agent as the aerosolized anthrax spores can cause fatal respiratory infections.<\/p>\n

About GC Biopharma<\/b><\/p>\n

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea<\/span>. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo\u2122(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit https:\/\/www.gcbiopharma.com\/eng\/<\/a><\/p>\n

This press release may contain<\/i>\u00a0biopharmaceuticals\u00a0in forward-looking statements, which express the current beliefs and expectations of GC Biopharma’s management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.<\/i><\/p>\n

GC Biopharma Contacts (Media)<\/b><\/p>\n

Sohee Kim<\/span><\/p>\n

shkim20@gccorp.com<\/a><\/p>\n

Yelin Jun<\/span><\/p>\n

yelin@gccorp.com<\/a><\/p>\n

Yoonjae Na<\/span><\/p>\n

yjy6520@gccorp.com<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-37565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37565"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37565\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}